Nothing Special   »   [go: up one dir, main page]

FR2940125B1 - Composition cosmetique ou pharmaceutique apaisante comprenant un peptide activateur de la hmg-coa reductase - Google Patents

Composition cosmetique ou pharmaceutique apaisante comprenant un peptide activateur de la hmg-coa reductase

Info

Publication number
FR2940125B1
FR2940125B1 FR0807365A FR0807365A FR2940125B1 FR 2940125 B1 FR2940125 B1 FR 2940125B1 FR 0807365 A FR0807365 A FR 0807365A FR 0807365 A FR0807365 A FR 0807365A FR 2940125 B1 FR2940125 B1 FR 2940125B1
Authority
FR
France
Prior art keywords
hmg
cosmetic
pharmaceutical
coa reductase
activator peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0807365A
Other languages
English (en)
Other versions
FR2940125A1 (fr
Inventor
Farra Claude Dal
Nouha Domloge
Jean Marie Botto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ISP Investments LLC
Original Assignee
ISP Investments LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ISP Investments LLC filed Critical ISP Investments LLC
Priority to FR0807365A priority Critical patent/FR2940125B1/fr
Priority to US13/141,392 priority patent/US8546340B2/en
Priority to PCT/FR2009/001477 priority patent/WO2010072928A1/fr
Publication of FR2940125A1 publication Critical patent/FR2940125A1/fr
Application granted granted Critical
Publication of FR2940125B1 publication Critical patent/FR2940125B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
FR0807365A 2008-12-23 2008-12-23 Composition cosmetique ou pharmaceutique apaisante comprenant un peptide activateur de la hmg-coa reductase Expired - Fee Related FR2940125B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR0807365A FR2940125B1 (fr) 2008-12-23 2008-12-23 Composition cosmetique ou pharmaceutique apaisante comprenant un peptide activateur de la hmg-coa reductase
US13/141,392 US8546340B2 (en) 2008-12-23 2009-12-23 Soothing pharmaceutical or cosmetic composition comprising a peptide that activates HMG-CoA reductase
PCT/FR2009/001477 WO2010072928A1 (fr) 2008-12-23 2009-12-23 Composition cosmetique ou pharmaceutique apaisante comprenant un peptide activateur de la hmg-coa reductase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0807365A FR2940125B1 (fr) 2008-12-23 2008-12-23 Composition cosmetique ou pharmaceutique apaisante comprenant un peptide activateur de la hmg-coa reductase

Publications (2)

Publication Number Publication Date
FR2940125A1 FR2940125A1 (fr) 2010-06-25
FR2940125B1 true FR2940125B1 (fr) 2013-03-22

Family

ID=40934893

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0807365A Expired - Fee Related FR2940125B1 (fr) 2008-12-23 2008-12-23 Composition cosmetique ou pharmaceutique apaisante comprenant un peptide activateur de la hmg-coa reductase

Country Status (3)

Country Link
US (1) US8546340B2 (fr)
FR (1) FR2940125B1 (fr)
WO (1) WO2010072928A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111979289B (zh) * 2020-07-22 2024-05-17 上海珈凯生物股份有限公司 植提物抵抗皮肤化学性刺激的细胞学评价方法及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
JP2751161B2 (ja) 1986-10-13 1998-05-18 味の素株式会社 栄養組成物
EP0738510A3 (fr) 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
US6346379B1 (en) * 1997-09-11 2002-02-12 F. Hoffman-La Roche Ag Thermostable DNA polymerases incorporating nucleoside triphosphates labeled with fluorescein family dyes
FR2789312B1 (fr) 1999-02-05 2003-10-17 Seporga Sterol 3 sulfates, nouveaux principes actifs a usage cosmetique et dermatologique, et leurs applications
FR2798591B1 (fr) 1999-09-22 2001-10-26 Pharmascience Lab Utilisation d'un produit d'huile vegetale pour augmenter la synthese des lipides cutanes en cosmetique, pharmacie ou dermatologie et en tant qu'additif alimentaire
CN101613397A (zh) 1999-10-29 2009-12-30 启龙股份公司 奈瑟球菌的抗原性肽
US6365138B1 (en) 2000-04-07 2002-04-02 The Regents Of The University Of California Compositions for metabolic protection and repair of lips
US7179590B2 (en) 2000-04-18 2007-02-20 Roche Molecular Systems, Inc High temperature reverse transcription using mutant DNA polymerases
TNSN02063A1 (en) 2001-07-07 2005-12-23 Egyptian Natural Oil Co Natoil The medical effect of jojoba oil
FR2827174B1 (fr) 2001-07-13 2004-08-06 Soc Extraction Principes Actif Utilisation de peptides pour augmenter l'adhesion cellulaire
US20030100467A1 (en) 2001-09-12 2003-05-29 Wolfgang Aehle Binding phenol oxidizing enzyme-peptide complexes
DE10206353A1 (de) 2002-02-14 2003-08-28 Cognis Deutschland Gmbh Verwendung von niedermolekularen Proteinhydralysaten
GB0208331D0 (en) * 2002-04-11 2002-05-22 Oxford Glycosciences Uk Ltd Proteins
EP1578432A4 (fr) * 2002-10-03 2008-07-30 Epimmune Inc Peptides de liaison hla et utilisations de ces derniers
FR2848851B1 (fr) 2002-12-20 2006-03-10 Procede d'obtention d'un principe actif presentant des capacites apaisantes, principe actif et compositions obtenues
FR2854069B1 (fr) 2003-04-23 2006-03-10 Silab Sa Procede d'obtention d'un principe actif a partir du soja, ayant des proprietes anti-vieillissement, compositions et utilisations de ces compositions a visee cosmetique
US20050142137A1 (en) 2003-11-07 2005-06-30 Curagen Corporation Antibodies against secretoryleukocyte protease inhibitor
WO2005080985A2 (fr) * 2004-02-18 2005-09-01 Enteron Limited Partnership Methodes et compositions permettant de detecter et de traiter des maladies auto-immunes
FR2868309B1 (fr) * 2004-04-02 2006-05-26 Oreal Utilisation cosmetique d'au moins un inhibiteur d'hmg-coa-reductase comme agent destine a prevenir et/ou lutter contre les rides d'expression
FR2869228B1 (fr) 2004-04-21 2008-09-05 Vincience Sa Utilisation d'un hydrolysat de proteines de cruciferes en tant qu'agent depigmentant dans ou pour une composition cosmetique et/ou pharmaceutique
US20060263787A1 (en) * 2004-05-10 2006-11-23 Evans Glen A Immunoglobulin-like variable chain binding polypeptides and methods of use
JP2008516928A (ja) 2004-10-14 2008-05-22 シムライズ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング・ウント・コンパニー・コマンジツト・ゲゼルシヤフト 損傷を受けていない皮膚の障壁機能を増強する方法
FR2904552B1 (fr) 2006-08-03 2012-09-21 Soc Extraction Principes Actif Utilisation d'un extrait de levure en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes
FR2911779B1 (fr) 2007-01-30 2009-04-24 Lvmh Rech Composition contenant un extrait d'ambre
FR2915384B1 (fr) 2007-04-27 2010-01-15 Vincience Utilisation d'un principe actif issu du soja (glycine maxl.) pour preparer une composition destinee a activer l'energie cellulaire et a proteger la peau des dommages oxydatifs.
FR2925330B1 (fr) 2007-12-21 2010-04-09 Vincience Utilisation d'un hydrolysat de pomme de terre en tant que principe actif activateur de la synthese des aquaporines
FR2925327A1 (fr) 2007-12-21 2009-06-26 Vincience Sa Utilisation d'un hydrolysat d'epeautre en tant que principe actif activateur de la synthese des aquaporines
FR2925325B1 (fr) 2007-12-21 2010-02-26 Vincience Utilisation d'un hydrolysat de colza en tant que principe actif activateur de la synthese des aquaporines
FR2925326B1 (fr) 2007-12-21 2010-02-26 Vincience Utilisation d'un hydrolysat de mais en tant que principe actif activateur de la synthese des aquaporines

Also Published As

Publication number Publication date
WO2010072928A1 (fr) 2010-07-01
FR2940125A1 (fr) 2010-06-25
US8546340B2 (en) 2013-10-01
US20110318433A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
FR2944526B1 (fr) Composition cosmetique et/ou pharmaceutique comprenant un hydrolysat peptidique capable de renforcer la fonction barriere
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI0917661A2 (pt) produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
BRPI0913726A2 (pt) rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos
FR2961814B1 (fr) Nouveaux peptides activateurs de la sirtuine 6 et composition cosmetique ou pharmaceutiques les comprenant.
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0812575A2 (pt) Uso de uma substância, composição cosmética ou dermo-cosmética ou neutracêutica, composição farmacêutica, método de cuidado cosmético, e, sequência de nucleotídeos
BR112013011868A2 (pt) compostos de pirimidina hidróxi amida como inibidores da proteína desacetilase, composição farmacêutica e uso dos referidos compostos
BR112012002855A2 (pt) "uso de um anticorpo anti-cd20 afucosilado e composição"
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
DK2300472T3 (da) Glucocorticoidmimetika, fremgangsmåder til disses fremstilling, farmaceutiske sammensætninger samt anvendelser deraf
BRPI0913410A2 (pt) uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica
BRPI0921699A2 (pt) complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
BRPI0908208A2 (pt) Composto derivado de oxazolidinona, medicamento, composição farmacêutica que o contém e uso desse composto.
FR18C1032I2 (fr) Anticorps anti-fgf23 et composition pharmaceutique le comprenant
BRPI0908859A2 (pt) composição farmacêutica estabilizada de líquído único contedo docetaxel
DE602006011790D1 (de) Lösungsmittelfreie formulierung von triclopyr-butoxyethylester
BRPI0916069A2 (pt) "composto, usos de um composto, composição farmacêutica, composição cosmética e usos cosméticos de uma composição"
FR2949782B1 (fr) Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant.
FR2958159B1 (fr) Compostion cosmetique ou pharmaceutique
BRPI0910570A2 (pt) uso de bioconjugados, e, formulações farmacêuticas
BRPI0822782A2 (pt) composição farmacêutica que compreende rosuvastatina
DE502007004811D1 (de) Flüssigformulierung von pyrethroiden
FR2882810B1 (fr) Generateur de glacons de produits liquides ou pateux

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

ST Notification of lapse

Effective date: 20200910